Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 23:8:740855.
doi: 10.3389/fnut.2021.740855. eCollection 2021.

Association of Serum 25-Hydroxyvitamin D Concentrations With All-Cause and Cause-Specific Mortality Among Adult Patients With Existing Cardiovascular Disease

Affiliations

Association of Serum 25-Hydroxyvitamin D Concentrations With All-Cause and Cause-Specific Mortality Among Adult Patients With Existing Cardiovascular Disease

Lei Dai et al. Front Nutr. .

Abstract

Background: Vitamin D insufficiency and deficiency are common in patients with cardiovascular disease (CVD). We aimed to prospectively examine the associations of serum 25-hydroxyvitamin D [25(OH)D] concentrations with all-cause and cause-specific mortality among adult patients with existing CVD. Methods: We included 37,079 patients with CVD from the UK Biobank study, a prospective cohort of half a million participants aged 40-69 years. We defined patients with CVD as those who suffered coronary heart disease, atrial fibrillation, heart failure, or stroke. The associations of serum 25(OH)D concentration with all-cause and cause-specific mortality were examined by using multivariable Cox regression models and competing risk analyses. Results: Among 37,079 patients with CVD at baseline, 57.5% were subjected to vitamin D deficiency (i.e., 25[OH]D <50 nmol/L). During a median follow-up of 11.7 years, 6,319 total deaths occurred, including 2,161 deaths from CVD, 2,230 deaths from cancer, 623 deaths from respiratory disease, and 1,305 other-cause deaths. We observed non-linear inverse associations for all-cause, cancer, respiratory disease, and other-cause mortality (P-non-linearity <0.01) and approximately linear inverse associations for CVD mortality (P-non-linearity = 0.074). Among CVD patients with vitamin D deficiency, per 10 nmol/L increment in serum 25(OH)D concentrations was associated with an 12% reduced risk for all-cause mortality and 9% reduced risk for CVD mortality. Conclusion: Among patients with existing CVD, increasing levels in serum 25(OH)D were independently associated with a decreased risk of all-cause and cause-specific mortality. These findings suggest that elevated serum 25(OH)D concentration benefits CVD patients with vitamin D deficiency.

Keywords: UK Biobank; cardiovascular disease; cohort study; mortality; vitamin D.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Dose-response curves for serum 25(OH)D concentrations and all-cause and cardiovascular mortality. Hazard ratios (blue lines) and 95% confidence intervals (light blue shade) were adjusted for age (continuous), sex (male, female), and ethnicity (White, mixed, Asian, Black, Chinese, others, or unknown), education (college or university, vocational qualification, upper secondary, lower secondary, others, or unknown), Townsend deprivation index (in quintiles), household income (<18,000, 18,000–30,999, 31,000–51,999, 52,000–1,00,000, >1,00,000 £, or unknown), smoking status (never smoker, former smoker, current smoker, or unknown), alcohol consumption (0, 0.1–4.9, 5.0–14.9, 15.0–19.9, 20.0–29.9, ≥30.0 g/day, or unknown), physical activity (inactive group, insufficient group, active group, or unknown), healthy diet score (in quintiles), and BMI (<18.5, 18.5–22.9, 23.0–24.9, 25.0–29.9, 30.0–34.9, or ≥35.0 kg/m2), eGFRcr-cys (<30.0, 30.0–60.0, 60.0–90.0, ≥90.0 ml min−1 per 1.73 m2), C-reactive protein (in quintiles), antihypertensive medication use (yes, no), cholesterol lowering medication use (yes, no), diabetes medication use (none, only oral medication, only insulin, or insulin and oral medication), history of cancer, diabetes, hypertension, and duration of CVD (<1.0, 1.0–4.9, 5.0–9.9, or ≥10.0 years). BMI, body mass index; CVD, cardiovascular disease; eGFRcr-cys, estimated glomerular filtration rate (creatinine–cystatin C equation).

Similar articles

Cited by

References

    1. GBD 2017 Causes of Death Collaborators . Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. (2018) 392:1736–88. 10.1016/S0140-6736(18)32203-7 - DOI - PMC - PubMed
    1. Pilz S, Verheyen N, Grübler MR, Tomaschitz A, März W. Vitamin D and cardiovascular disease prevention. Nat Rev Cardiol. (2016) 13:404–17. 10.1038/nrcardio.2016.73 - DOI - PubMed
    1. Michos ED, Cainzos-Achirica M, Heravi AS, Appel LJ. Vitamin D, calcium supplements, and implications for cardiovascular health: JACC focus seminar. J Am Coll Cardiol. (2021) 77:437–49. 10.1016/j.jacc.2020.09.617 - DOI - PubMed
    1. Chin K, Zhao D, Tibuakuu M, Martin SS, Ndumele CE, Florido R, et al. . Physical activity, vitamin D, and incident atherosclerotic cardiovascular disease in whites and blacks: the ARIC study. J Clin Endocrinol Metab. (2017) 102:1227–36. 10.1210/jc.2016-3743 - DOI - PMC - PubMed
    1. Lutsey PL, Michos ED, Misialek JR, Pankow JS, Loehr L, Selvin E, et al. . Race and vitamin D binding protein gene polymorphisms modify the association of 25-hydroxyvitamin D and incident heart failure: the ARIC (Atherosclerosis Risk in Communities) study. JACC Heart Fail. (2015) 3:347–56. 10.1016/j.jchf.2014.11.013 - DOI - PMC - PubMed

LinkOut - more resources